Search | Clinical Trials Finder

Conditions: Thromboembolism
Interventions: Pharmacogenetic, Target INR 1.8; Genetic · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years and older
Enrollment: 1,598 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 6
States / cities: Chicago, Illinois • St Louis, Missouri • New York, New York + 2 more

Conditions: Deep Vein Thrombosis, Venous Thrombosis
Interventions: edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 29
States / cities: Dothan, Alabama • Montgomery, Alabama • Sacramento, California + 26 more

Conditions: Psoriasis
Interventions: Drug Cocktail, Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Anaheim, California • DeLand, Florida • High Point, North Carolina

Conditions: Heart Failure
Interventions: Apixaban, Warfarin, LVAD implant; Drug · Device
Lead sponsor: Palak Shah; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Dementia, Cognition Disorders, Cerebral Ischemic Events
Interventions: Dabigatran Etexilate, Warfarin; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 65 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Bradycardia, Tachycardia, Atrial Fibrillation, Valvular Heart Disease
Interventions: continue warfarin through the procedure, Hold warfarin, Warfarin held with heparin transition.; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbia, Maryland

Conditions: Crohn Disease, Ulcerative Colitis
Interventions: Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Cypress, California • Miami Springs, Florida • Durham, North Carolina

Conditions: Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions: Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care; Other · Diagnostic Test
Lead sponsor: Region Skane; Other
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Atrial Fibrillation, Ischemic Stroke, Peripheral Thromboembolism
Interventions: AMPLATZER Cardiac Plug; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Aurora, Colorado • Littleton, Colorado + 13 more

Conditions: Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions: Warfarin GenoSTAT Test; Device
Lead sponsor: Iverson Genetic Diagnostics, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 3,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 56
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more

Conditions: Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial, Major Bleeding
Interventions: Home Monitoring Guided OAC, Physician-Directed OAC; Drug
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 73
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more

Conditions: Pulmonary Embolism
Interventions: SR34006, (LMW)heparin, Warfarin VKA, Acenocoumarol VKA; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 54
States / cities: Loma Linda, California • San Diego, California • Aurora, Colorado + 43 more

Conditions: Patent Foramen Ovale, Stroke, Ischemic Attack, Transient
Interventions: STARFlex septal closure system, Best medical therapy; Device · Drug
Lead sponsor: NMT Medical; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Heart Failure
Interventions: HeartMate II (HMII), Warfarin, acetylsalicylic acid (ASA) therapy; Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 50 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 33
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more

Conditions: Pulmonary Embolism
Interventions: FlowTriever System, Anticoagulation Agents; Device · Drug
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 42
States / cities: Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more

Conditions: Venous Thromboembolism (VTE)
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 35,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 333,664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Evacetrapib, Warfarin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Coagulation Delay
Interventions: phytonadione; Dietary Supplement
Lead sponsor: James A. Haley Veterans Administration Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Uterine Hemorrhage
Interventions: Direct oral anticoagulant (DOACs), Warfarin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 961,985 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Atrial Fibrillation
Interventions: Edoxaban, Warfarin, Enoxaparin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 2,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 28
States / cities: Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: warfarin, apixaban; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 20,976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 284
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more

Conditions: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Standard of care or genotyping dosing of warfarin dosing; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Anticoagulation, Anticoagulation Reversal
Interventions: four factor prothrombin complex concentrate; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

A Study of Mirikizumab in Participants With Plaque Psoriasis

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

International Care Bundle Evaluation in Cerebral Hemorrhage Research

AMPLATZER Cardiac Plug Clinical Trial

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

The PEERLESS II Study

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Anticoagulant Utilization Pattern

A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Use of Phytonadione to Reduce International Normalized Ratio (INR) Variability in Patients on Long-term Warfarin Therapy

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"

Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)